Highlights

  • D. Boral Capital reissued its "buy" rating for Trevi Therapeutics with a $19.00 target.
  • Weiss Ratings maintained a "sell (d-)" rating on the stock.
  • Trevi Therapeutics currently holds a "Moderate Buy" consensus rating from analysts.

Trevi Therapeutics (NASDAQ:TRVI) has received a series of updates from research firms in recent days. D. Boral Capital reaffirmed its "buy" rating on the stock with a target price of $19.00, suggesting a potential upside from the stock's most recent close. This aligns with other analysts who have recently weighed in on the company.

Oppenheimer raised its price target on Trevi Therapeutics from $23.00 to $24.00, maintaining an "outperform" rating. Similarly, Morgan Stanley increased its target from $18.00 to $19.00 and also rated the stock "overweight." On the other hand, Weiss Ratings issued a "sell (d-)" rating on the stock, reflecting a more cautious outlook.

Further, Raymond James adjusted their price target on Trevi Therapeutics from $29.00 to $27.00, while keeping a "strong-buy" rating. Meanwhile, Leerink Partners initiated coverage on Trevi with an "outperform" rating and set a target price of $13.00.

Consensus Rating and Target Price

Currently, Trevi Therapeutics has an average analyst rating of "Moderate Buy" from a mix of research firms. The stock has one analyst rating it a "Strong Buy," eight rating it as "Buy," and one analyst assigning a "Sell" rating. The consensus target price is $21.11, which is slightly higher than its current trading level.

Institutional Investors

Trevi Therapeutics has also seen notable changes in institutional investor positions. Russell Investments Group Ltd. increased its stake by 194.5%, now holding over 4,500 shares. Farther Finance Advisors LLC grew its holdings by 15,969.1%, while Strs Ohio, Catalyst Funds Management, and Rafferty Asset Management also added positions during the recent quarter. Hedge funds and institutional investors currently own 95.76% of the company's stock.

Company Overview

Trevi Therapeutics is a clinical-stage biopharmaceutical company focusing on developing therapies for chronic conditions. Its primary candidate, Haduvio, targets central and peripheral nervous systems to treat chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC).